PG
BMRN icon

PEAK6 Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

PEAK6 Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$8.24M Sell
87,517
-28,857
-25% -$2.53M 0.04% 533
2018
Q1 		$9.43M Buy
116,374
+59,510
+105% +$5.11M 0.04% 478
2017
Q4 		$5.07M Buy
56,864
+36,698
+182% +$3.19M 0.02% 808
2017
Q3 		$1.88M Buy
20,166
+9,162
+83% +$810K 0.01% 1444
2017
Q2 		$999K Sell
11,004
-48,970
-82% -$4.46M 0.01% 1927
2017
Q1 		$5.26M Buy
59,974
+34,417
+135% +$3.06M 0.04% 548
2016
Q4 		$2.12M Buy
+25,557
New +$2.2M 0.02% 1268
2016
Q3 		– Sell
-11,193
Closed -$1.05M – 4311
2016
Q2 		$871K Buy
+11,193
New +$952K 0.01% 1912
2016
Q1 		– Sell
-42,706
Closed -$3.47M – 4407
2015
Q4 		$4.47M Sell
42,706
-25,812
-38% -$2.7M 0.03% 804
2015
Q3 		$7.22M Buy
68,518
+9,456
+16% +$1.26M 0.04% 659
2015
Q2 		$8.08M Buy
59,062
+39,407
+200% +$4.88M 0.05% 544
2015
Q1 		$2.45M Buy
+19,655
New +$2.08M 0.02% 1112
2014
Q4 		– Sell
-41,549
Closed -$3.46M – 4660
2014
Q3 		$3M Buy
41,549
+20,549
+98% +$1.35M 0.02% 952
2014
Q2 		$1.31M Buy
21,000
+11,500
+121% +$695K 0.01% 1417
2014
Q1 		$648K Buy
9,500
+100
+1% +$7.37K 0.01% 2291
2013
Q4 		$661K Buy
+9,400
New +$638K ﹤0.01% 2421
2013
Q3 		– Sell
-2,500
Closed -$166K – 5102
2013
Q2 		$139K Buy
+2,500
New +$156K ﹤0.01% 3896

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

PEAK6 Group's BMRN Position: Q2 2018 in Review

PEAK6 Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2018, selling an estimated $2.53M and leaving 87,517 shares worth $8.24M. The position accounts for 0.04% of the portfolio, ranked #533.

PEAK6 Group first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.43M in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • PEAK6 Group held 87,517 shares of BioMarin Pharmaceuticals worth $8.24M as of Q2 2018.
  • PEAK6 Group sold 28,857 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2.53M.
  • BioMarin Pharmaceuticals made up 0.04% of PEAK6 Group's portfolio in Q2 2018, its #533 holding.
  • PEAK6 Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • PEAK6 Group's BioMarin Pharmaceuticals position peaked at $9.43M in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.